Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malaria

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 36 articles:
HTML format



Single Articles


    March 2024
  1. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    February 2024
  2. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  3. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    November 2023
  4. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    August 2023
  5. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    May 2023
  6. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    PubMed     Abstract available


    April 2023
  7. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    February 2023
  8. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    January 2023
  9. KABIR SULAIMAN S, Isma'il Tsiga-Ahmed F, Sale Musa M, Kabir Sulaiman A, et al
    Prevalence, determinants, and reasons for malaria vaccine hesitancy among caregivers of under-five children in Nigeria: Results from a nationwide cross-sectional survey.
    Vaccine. 2023 Jan 30:S0264-410X(23)00089-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  10. BARAL R, Levin A, Odero C, Pecenka C, et al
    Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Vaccine. 2023 Jan 27:S0264-410X(23)00064-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  11. DEVECI G, Kamil M, Aly ASI
    A single dose of genetically-attenuated malaria blood-stage parasites protects against two Plasmodium species infections.
    Vaccine. 2023 Jan 16:S0264-410X(23)00003-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  12. BELMONTE M, Ganeshan H, Huang J, Belmonte A, et al
    Immunodominant T cell peptides from four candidate malarial antigens as biomarkers of protective immunity against malaria.
    Vaccine. 2023 Jan 13:S0264-410X(23)00027-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  13. BAI J, Liu F, Yang F, Zhao Y, et al
    Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.
    Vaccine. 2023;41:555-563.
    PubMed     Abstract available


    December 2022
  14. TOTTEY S, Shoji Y, Mark Jones R, Musiychuk K, et al
    Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.
    Vaccine. 2022 Dec 28:S0264-410X(22)01573-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    August 2022
  15. HUTTER JN, Robben PM, Lee C, Hamer M, et al
    First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01039.
    PubMed     Abstract available


    June 2022
  16. SCHNEIDER CG, Fey J, Zou X, Gerbasi V, et al
    Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00701.
    PubMed     Abstract available


    January 2022
  17. AREVALO-HERRERA M, Miura K, Solano E, Sebastian Ramirez J, et al
    Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.
    Vaccine. 2022;40:133-140.
    PubMed     Abstract available


    December 2021
  18. KUSI KA, Ofori EA, Akyea-Mensah K, Kyei-Baafour E, et al
    Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01650.
    PubMed     Abstract available


  19. RANADE D, Jena R, Sancheti S, Deore V, et al
    Rapid, high throughput protein estimation method for saponin and alhydrogel adjuvanted R21 VLP Malaria vaccine based on intrinsic fluorescence.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01627.
    PubMed     Abstract available


    September 2021
  20. MOON JE, Greenleaf ME, Regules JA, Debois M, et al
    A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01203.
    PubMed     Abstract available


    June 2021
  21. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    PubMed     Abstract available


    April 2021
  22. VEKEMANS J, Schellenberg D, Benns S, O'Brien K, et al
    Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00409.
    PubMed     Abstract available


  23. DE SL, May S, Shah K, Slawinski M, et al
    Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00376.
    PubMed     Abstract available


    February 2021
  24. DAS SC, Price JD, Gosling K, MacLennan N, et al
    Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00158.
    PubMed     Abstract available


    January 2021
  25. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    PubMed     Abstract available


  26. CHAUDHURY S, MacGill RS, Early AM, Bolton JS, et al
    Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31635.
    PubMed     Abstract available


    December 2020
  27. SUAU R, Vidal M, Aguilar R, Ruiz-Olalla G, et al
    RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31606.
    PubMed     Abstract available


    October 2020
  28. MO AXY, Pesce J, Augustine AD, Bodmer JL, et al
    Understanding vaccine-elicited protective immunity against pre-erythrocytic stage malaria in endemic regions.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31253.
    PubMed     Abstract available


  29. THOMPSON HA, Hogan AB, Walker PGT, White MT, et al
    Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31251.
    PubMed     Abstract available


  30. EZOE S, Palacpac NMQ, Tetsutani K, Yamamoto K, et al
    First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31227.
    PubMed     Abstract available


    September 2020
  31. VAN DER GRAAF R, Macklin R, Rid A, Bhan A, et al
    Integrating public health programs and research after the malaria vaccine implementation program (MVIP): Recommendations for next steps.
    Vaccine. 2020 Sep 24. pii: S0264-410X(20)31132.
    PubMed     Abstract available


    June 2020
  32. OUATTARA A, Niangaly A, Adams M, Coulibaly D, et al
    Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30821.
    PubMed     Abstract available


    May 2020
  33. ONEKO M, Cherop YR, Sang T, Gutman JR, et al
    Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya.
    Vaccine. 2020 May 19. pii: S0264-410X(20)30614.
    PubMed     Abstract available


    March 2020
  34. TACHIBANA M, Baba M, Takashima E, Tsuboi T, et al
    The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice.
    Vaccine. 2020;38:3129-3136.
    PubMed     Abstract available


    February 2020
  35. QIU Y, Zhao Y, Liu F, Ye B, et al
    Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.
    Vaccine. 2020 Feb 21. pii: S0264-410X(20)30184.
    PubMed     Abstract available


  36. SSEMAGANDA A, Giddam AK, Low LM, Liu XQ, et al
    Mannosylated liposomes formulated with whole parasite P. falciparum blood-stage antigens are highly immunogenic in mice.
    Vaccine. 2020;38:1494-1504.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malaria is free of charge.